Key Takeaways
- Consolidated revenue down 7% YoY, but margins improved: Q4 gross margins were maintained at 30% and EBITDA margins at around 13.4%, while FY23 gross margins rose to 29% from 25% and EBITDA margins to 13.5% from 12.4%, driven by consistent performance improvement across the portfolio.
- Subsidiary growth masked by consolidation mechanics: Unitop and Tristar both grew over 20% YoY on a like-to-like basis, but inter-company eliminations and a strategic shift to route sales through Rossari's network obscure that growth at the consolidated top line.
- A large HPPC customer exit was absorbed quickly: The loss of one major account created a visible hole in Q4, but the gap was being filled by new detergent customers and an initial engagement with HUL across two plants, with full recovery expected within a couple of quarters.
- Management set an internal target of 20% absolute EBITDA growth for FY24, paired with a projected 30% bottom-line expansion, while explicitly deprioritizing top-line and margin-percentage metrics. The 30% bottom-line growth was stated as an internal budget projection, not a formal guidance.
- What to watch next quarter: Whether the textile demand recovery promised for H2 actually materializes, the pace of new customer onboarding in HPPC to offset the lost large account, and the revenue contribution from the new vitamin premix facility once it comes online in late Q2.
The Consolidation Story: Why Reported Revenue Understates Growth
- Unitop grew ~20% despite raw material price headwinds: Revenue rose from ~₹454 crore to ₹554 crore; management estimates that on prior-year raw material prices, revenue would have been ~₹600-625 crore, implying a 10-15% price-driven drag.
- Tristar achieved 27% like-to-like growth (₹164 crore to ₹209 crore) even as phenol and phenoxyethanol prices fell and European export demand weakened after the Ukraine war. New customers brought in by Rossari offset the export pressure.
- Inter-company eliminations are a growing distortion: Sales from Tristar and Unitop to Rossari get neutralized in consolidation, and Rossari's shift to source ethoxylates from Unitop (instead of externally) further reduces visible third-party sales. The base period also had fewer eliminations because EO was unavailable from Unitop until August FY22.
- Cross-selling strategy deliberately shifts margin geography: Tristar and Unitop sales are increasingly routed through Rossari's customer network, with part of the margin booked at Rossari and part at the subsidiary at arm's length. Management insists the consolidated view is the only representative one.
Ketan Sablok: "The request would be that the ideal way to now start looking at the numbers is on a consolidated level because certain part of the margin will remain in Rossari and certain part of the margin will remain in the subsidiary."
Segment Performance: HPPC Absorbs a Hit, Textiles Lags, AHN Surges
| Segment | Trend | Commentary |
|---|---|---|
| HPPC | ▬ Resilient | Lost one large customer (zero sales in Q4 vs a significant chunk in Q4 last year), yet sales were maintained through smaller detergent clients and a new HUL engagement across two plants. Now 70% of consolidated sales, up from 50% two years ago. |
| Textiles | ▼ Weak | Degrew overall; sequential growth of 10% in Q4 came from new product additions, but underlying demand remains sluggish and unpredictable. Recovery expected only in H2 FY24. |
| AHN | ▲ Strong | Year-end revenue of ₹81.2 crore driven by new customer additions and an aggressive entry into vitamins and minerals. Management is bullish and targets doubling revenue in two to three years. |
| Tristar (consolidated) | ▲ Growth | 27% like-to-like growth despite European export pressure; new Rossari-sourced customers compensated for the decline. |
- HPPC recovery timeline: Management expects to fully cover the revenue loss from the large customer exit within a couple of quarters, aided by the HUL ramp-up and freedom to now sell detergent ingredients across India and neighboring Southeast Asian markets.
- Textile caution: Demand is expected to pick up from H2 FY24 based on customer conversations, but management remains guarded because the segment has repeatedly disappointed.
Ketan Sablok: "Textile has been acting crazy over the last year. So, every time we think that the worst is over, it really doesn't happen. But currently, this is what the understanding is."
Margin Walk: A One-Time Settlement and Export Pressure Weighed on Q4
- Consolidated EBITDA remained stagnant at about ₹54–55 crore because a one-time full and final settlement of ₹2.5–3 crore to senior Tristar directors was booked in other expenses. Excluding this, underlying EBITDA would have shown growth.
- Consolidated gross profit margin fell 40 bps sequentially because Tristar's export margins were hit significantly as European volumes came down sharply. The cross-selling margin allocation between entities adds noise; management urges a consolidated view.
- Full-year margin trajectory is the brighter story: FY23 gross margins improved to 29% from 25% and EBITDA margins to 13.5% from 12.4%, reflecting consistent operational improvement across the portfolio.
- Raw material discipline is now policy: After learning what management called a lesson from FY2021-22 and FY2022-23, the company will not take large raw material positions, will not enter long-term fixed-price contracts with customers, and will never hedge forex.
Sunil Chari: "We learnt a lesson from FY2021-22 and FY2022-23 that we will not do any forward provisions and we do not do any long contracts with our customers... Similarly, Forex, we have never hedged, and we will never hedge also."
New Product Pipeline and Strategic Initiatives
- FDA approval secured: A pharma tablet coating product received FDA approval, with production likely to start in the coming quarter, opening a new regulated end-market.
- Multiple new product launches: An anti-depressant product for liquid detergents (where normal ARDs are incompatible), highly modified coating chemicals with better scrub properties for paints and ceramics, a silicone wax for yarn lubricants, and additives for regenerated cellulose (lyocell) were all introduced.
- In-house silicone manufacturing began: The company started manufacturing silicone oils and block silicones in-house, increasing flexibility and reducing dependence on external sourcing. A Capex program to scale silicone super wetters has also started.
- Granulation facility installed: A new granulation unit at the plant improves production efficiency and enables product differentiation.
- Bio-surfactant in development: Management is working on a bio-based product for use as a surfactant and is excited to introduce it in a few months.
- Vitamin premix Capex nearing completion: A small Capex for a vitamin premix setup at Dahej is a few months from completion; meaningful sales are anticipated from the latter half of Q2 and into Q3.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated EBITDA growth | 20% growth in absolute EBITDA over FY23 consolidated EBITDA (internal target) | FY24 |
| Bottom-line growth | 30% growth projected in internal budget | FY24 |
| HPPC large customer loss recovery | Fully cover the revenue loss from the exited account | Within a couple of quarters |
| Textile demand recovery | Demand uptick expected | H2 FY24 |
| AHN revenue doubling | Double AHN revenue from current base (~₹125 crore) | Next 2–3 years |
| Unitop full acquisition | Acquire remaining stake to make Unitop 100% owned | August 2023 |
| Merger completion | Rossari, Unitop, and Tristar as one consolidated legal entity | By 31st March 2024 |
| Vitamin premix facility | Start generating meaningful sales | Latter half of Q2 / Q3 FY24 |
| Capex | ₹40–50 crore per year | FY24 and FY25 |
| Asset turns | 4–5x on a consolidated basis | FY24 |
| Interest cost | Slightly lower than FY23 | FY24 |
| Bio-surfactant launch | Introduce new bio-based surfactant product | A few months |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Consolidated revenue | ₹406.5 crore, up from ₹389.3 crore in Q3 FY23 |
| Standalone revenue | ₹263.6 crore, up 11.3% QoQ from ₹236.9 crore in Q3 FY23 |
| Consolidated gross margin | 30%, maintained YoY despite 7% revenue decline |
| Consolidated EBITDA | ₹54.6 crore, vs ₹54.2 crore in Q3 FY23; includes ₹2.5–3 crore one-time settlement impact |
| Consolidated EBITDA margin | ~13.4%, EBITDA grew 4% YoY |
| Consolidated PAT | ₹29 crore, vs ₹25.7 crore in Q3 FY23 |
| Standalone EBITDA | ₹35.8 crore, vs ₹31.9 crore in Q3 FY23 |
| Standalone PAT | ₹23.1 crore, vs ₹17.5 crore in Q3 FY23 |
| FY23 consolidated revenue | ₹1,655.9 crore, up 11.7% YoY |
| FY23 consolidated EBITDA | ₹122.7 crore, vs ₹122.8 crore in FY22; margin 12.6% |
| FY23 consolidated PAT | ₹107.3 crore, vs ₹97.7 crore in FY22 |
| FY23 gross margin | 29%, vs 25% in FY22 |
| FY23 EBITDA margin | 12.6%, vs 12.4% in FY22 |
| HPPC segment FY23 revenue | ₹1,157 crore, 70% of consolidated revenue |
| TSC segment FY23 revenue | ₹373.2 crore, 23% of consolidated revenue |
| AHN segment FY23 revenue | ₹125.7 crore, 7% of consolidated revenue |
| Unitop FY23 revenue | ₹554 crore, vs ₹454 crore in FY22; EBITDA ₹81 crore vs ₹69 crore |
| Tristar FY23 revenue | ₹209 crore, vs ₹164 crore in FY22; EBITDA ₹18 crore vs ₹17 crore |
| Unitop and Tristar combined FY23 revenue | ₹763.2 crore, EBITDA ₹98.5 crore; revenue growth of 23% and 13% respectively since FY2022 |
| FY23 exports | ₹380 crore, vs ₹264 crore in FY22 |
| Consolidated net cash | ₹77 crore as of March 2023 |
| Cash and cash equivalents | ₹69.8 crore as of March 2023 |
| Net cash flow from operating activities FY23 | ₹152.4 crore |
| FY23 depreciation | ₹62.9 crore, increased due to amortization of fair valuation on subsidiary consolidation |
| FY23 interest cost | ₹22.3 crore; includes accounting entry for M&A deferred consideration |
| Capacity utilization | 50–55% across most plants |
| Internal EBITDA growth target | 20% growth in consolidated EBITDA (absolute amount) for FY24 |
| Bottom-line growth projection | 30% (per management's internal budget, in response to analyst suggesting 25%) |
| Capex guidance FY24 | ₹40–50 crore |
| Tristar one-time settlement impact | ₹2.5–3 crore, booked in other expenses, impacted Q4 consolidated EBITDA |
| Net outgo for final Tristar tranche | ~₹17 crore, funded through internal accruals; Tristar now 100% subsidiary as of 12 April 2023 |